转移性结直肠癌患者一线FOLFIRI/贝伐珠单抗进展后接受伊立替康/西妥昔单抗序贯FOLFOX-4或相反顺序治疗的III期随机试验:意大利胃肠肿瘤研究组比较两种治疗序列的研究
本III期随机试验纳入一线FOLFIRI/贝伐珠单抗进展后的RAS野生型转移性结直肠癌患者,随机接受二线伊立替康/西妥昔单抗序贯三线FOLFOX-4(A组)或相反顺序(B组)。主要终点无进展生存期未达到,A组与B组中位无进展生存期分别为9.9个月与11.3个月(HR 1.04,95%CI 0.69-1.56,p=0.854),中位总生存期分别为12.3个月与18.6个月(HR 0.84,95%CI 0.55-1.28,p=0.411)。研究结果似乎提示一线贝伐珠单抗治疗后西妥昔单抗活性降低。
要点
- A组与B组中位无进展生存期分别为9.9个月与11.3个月(HR 1.04,95%CI 0.69-1.56,p=0.854),主要终点未达到。
- A组与B组中位总生存期分别为12.3个月与18.6个月(HR 0.84,95%CI 0.55-1.28,p=0.411)。
- 两组副作用无总体差异,研究似乎提示一线贝伐珠单抗后西妥昔单抗活性降低。
核心结论
- 本试验未达到主要终点无进展生存期。
- 与其他临床前和临床证据一致,本研究似乎提示一线贝伐珠单抗治疗后西妥昔单抗活性降低。
研究设计与样本
- 意大利胃肠肿瘤研究组开展的III期随机试验,纳入一线FOLFIRI/贝伐珠单抗进展后的转移性结直肠癌患者。
- A组54例接受二线伊立替康/西妥昔单抗序贯三线FOLFOX-4,B组56例接受相反顺序。
- 主要终点为无进展生存期。
主要发现
- 中位随访37.5个月,共记录100例无进展生存事件。
- A组与B组中位无进展生存期分别为9.9个月与11.3个月(HR 1.04,95%CI 0.69-1.56,p=0.854)。
- A组与B组中位总生存期分别为12.3个月与18.6个月(HR 0.84,95%CI 0.55-1.28,p=0.411)。
- 两组副作用无总体差异。
局限性
- 本试验未达到主要终点无进展生存期。
- 研究结果似乎提示一线贝伐珠单抗治疗后西妥昔单抗活性降低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The optimal treatment strategy for RAS wild type (WT) mCRC is controversial. Our phase III study investigated the effect of introducing earlier (second-line) or later (third-line) cetuximab in patients progressed after FOLFIRI/bevacizumab first-line. PATIENTS AND METHODS: mCRC patients progressing after FOLFIRI/bevacizumab first-line were randomised to receive second-line irinotecan/cetuximab followed by third-line FOLFOX-4 (arm A) or the reverse sequence (arm B). Primary end-point was progression-free survival (PFS). RESULTS: About 54 and 56 patients were randomised in arm A and in arm B, respectively. After a median follow-up of 37.5 months, 100 PFS events were recorded. Median PFS was 9.9 months in arm A and 11.3 months in arm B (Hazard ratio [HR] 1.04, 95% confidence interval [CI]: 0.69-1.56, p = 0.854), while median overall survival was 12.3 months in arm A and 18.6 months in arm B (HR 0.84, 95% CI: 0.55-1.28; p = 0.411). No overall difference in side-effects were observed between the two treatment arms. CONCLUSIONS: This trial did not meet the primary end-point (PFS). Like other preclinical and clinical evidences, our study seems to suggest a reduced activity of cetuximab after a first-line bevacizumab-based therapy.
引用
- Cascinu S, Rosati G, Nasti G, et al. Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients. Eur J Cancer. 2017. PMID: 28735067. doi:10.1016/j.ejca.2017.06.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。